Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$105.48

(0.00%)

, SLDB

Solid Biosciences

$27.00

-2.265 (-7.74%)

10:15
06/19/18
06/19
10:15
06/19/18
10:15

Sarepta gene therapy produced 'jaw-dropping' protein increases, STAT says

Sarepta Therapeutics' (SRPT) experimental gene therapy for Duchenne muscular dystrophy produced "jaw-dropping increases" in a crucial muscle protein normally missing in patients with the disease, STAT's Adam Feuerstein reports, citing preliminary clinical trial data released today. The data, consisting of only three boys, produced 38% of a truncated form of the normal dystrophin muscle protein, which is "profound enough to suggest it may halt or even reverse the effects of Duchenne in certain patients," Feuerstein writes. Shares of Sarepta remain halted as its R&D day remains ongoing. Shares of Solid Biosciences (SLDB) reversed an earlier selloff and are now up 9% to $31.99. Reference Link

SRPT

Sarepta

$105.48

(0.00%)

SLDB

Solid Biosciences

$27.00

-2.265 (-7.74%)

  • 20

    Jun

SRPT Sarepta
$105.48

(0.00%)

06/15/18
06/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PetMed Express (PETS) initiated with a Neutral at CL King. 2. Cloudera (CLDR) initiated with a Reduce at Nomura Instinet. 3. Sarepta (SRPT) initiated with a Buy at BTIG. 4. Delphi Technologies (DLPH) initiated with a Perform at Oppenheimer. 5. Enerplus (ERF) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/15/18
JPMS
06/15/18
NO CHANGE
JPMS
Overweight
JPMorgan sees favorable setup for Sarepta into Tuesday's event
JPMorgan analyst Anupam Rama sees a favorable setup for shares of Sarepta Therapeutics(SRPT) into the company's R&D day on Tuesday, June 19. His scenario analysis points to a "very favorable" reward/risk profile of 20%-50% upside versus 10%-25% downside. If the gene therapy data meets or beats expectations, Sarepta will clearly be in the pole position in the micro-dystrophin space, Rama tells investors in a research note. The analyst adds that if the Sarepta micro-dystrophin data are viewed positively next week, a clear bar will have been set that Solid Biosciences (SLDB) will need to meet or beat. Rama continues to see risk to Solid shares ahead of next week's readout from Sarepta. He has an Overweight rating on Sarepta with an $87 price target and Underweight rating on Solid Biosciences with a $10 price target.
06/15/18
BTIG
06/15/18
INITIATION
Target $120
BTIG
Buy
Sarepta initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started Sarepta Therapeutics with a Buy rating and $120 price target. The company is the leader in the Duchenne muscular dystrophy space with its Exondys 51 estimated to generate sales of $300M in 2018, and its "extensive pipeline" of RNA-splicing product candidates, Chiang tells investors in a research note. While the stock is up 78% year-to-date, there is the potential for further upside as investors get additional visibility on Sarepta's gene therapy and phosphorodiamidate morpholino oligomer programs, the analyst contends.
06/05/18
NOMU
06/05/18
NO CHANGE
Target $131
NOMU
Buy
Nomura Instinet positive on Dr. Rodino-Klapac joining Sarepta
Nomura Instinet analyst Christopher Marai views the appointment of Dr. Rodino-Klapac as Sarepta Therapeutics' Vice President of a newly created gene-therapy unit positively. The news further indicates that Sarepta is broadly expanding its gene therapy program in neuromuscular diseases, Marai tells investors in a research note. He reiterates a Buy rating on the shares with a $131 price target.
SLDB Solid Biosciences
$27.00

-2.265 (-7.74%)

05/15/18
LEER
05/15/18
NO CHANGE
Target $121
LEER
Outperform
Sarepta price target raised to $121 from $88 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta (SRPT) to $121 from $88, while reiterating an Outperform rating on the shares. The analyst notes that Sarepta is one of three companies developing microdystrophin gene therapy for Duchenne muscular dystrophy, in competition with Pfizer (PFE) who acquired Bamboo, and Solid Biosciences (SLDB). With Solid's clinical hold still in place, Sarepta could potentially be first-to-market, and is expected to report the first clinical data for a micro-dystrophin candidate at their R&D day on June 19, he adds.
05/10/18
LEER
05/10/18
NO CHANGE
Target $28
LEER
Outperform
Solid Biosciences price target raised to $28 from $14 at Leerink
Leerink analyst Joseph Schwartz raised his price target on Solid Biosciences to $28 from $14 after he updated his model to reflect Q1 results and increased his probability of success estimate for SGT-001 to 30% from 20%. His probability of success estimate for SB-001 is unchanged at 20%, he noted. Schwartz keeps an Outperform rating on Solid Biosciences shares.
04/02/18
LEER
04/02/18
NO CHANGE
Target $14
LEER
Outperform
Solid Biosciences price target lowered to $14 from $36 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Solid Biosciences to $14 from $36 saying that while it was able to withstand several initial concerns that were addressed when the company was going public - including preclinical safety, a board member resignation, manufacturing issues -, Solid Biosciences' recent clinical hold announcement was "the straw that broke the camel's back" resulting in a massive selloff. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SMBC

Southern Missouri Bancorp

$36.25

0.03 (0.08%)

17:32
10/22/18
10/22
17:32
10/22/18
17:32
Earnings
Southern Missouri Bancorp reports Q3 EPS 76c, consensus 69c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$12.19

-0.12 (-0.97%)

17:30
10/22/18
10/22
17:30
10/22/18
17:30
Hot Stocks
Breaking Hot Stocks news story on TimkenSteel »

Luminus Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

17:27
10/22/18
10/22
17:27
10/22/18
17:27
Syndicate
Chembio Diagnostics files to sell $25M of common stock »

Canaccord Genuity and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:23
10/22/18
10/22
17:23
10/22/18
17:23
Hot Stocks
Sallie Mae reports Q3 net interest margin up 15bps at 6.00% »

Q3 Private education loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:22
10/22/18
10/22
17:22
10/22/18
17:22
Earnings
Sallie Mae raises FY18 core EPS view to $1.02-$1.03 from 99c-$1.01 »

Consensus$1.02. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:19
10/22/18
10/22
17:19
10/22/18
17:19
Earnings
Sallie Mae reports Q3 adjusted EPS 23c, consensus 24c »

Reports Q3 NII $356.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

BA

Boeing

$355.98

-0.3 (-0.08%)

17:17
10/22/18
10/22
17:17
10/22/18
17:17
Hot Stocks
Correction: Boeing maintains quarterly dividend of $1.71 »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

, MAR

Marriott

$111.49

-0.58 (-0.52%)

17:15
10/22/18
10/22
17:15
10/22/18
17:15
Hot Stocks
St. Joe Company, InterMountain break ground on New Towneplace Suites Hotel »

The St. Joe Company (JOE)…

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

MAR

Marriott

$111.49

-0.58 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

RNST

Renasant

$35.44

-1.1 (-3.01%)

17:11
10/22/18
10/22
17:11
10/22/18
17:11
Earnings
Renasant reports Q3 adjusted EPS 61c, consensus 77c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Dec

IAG

IAMGold

$3.84

-0.13 (-3.27%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
IAMGold announces positive results from a feasibility study for Senegal project »

IAMGOLD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HWBK

Hawthorn Bancshares

$23.20

-0.27 (-1.15%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
Breaking Hot Stocks news story on Hawthorn Bancshares »

Endeavour Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:07
10/22/18
10/22
17:07
10/22/18
17:07
Earnings
Green Bancorp reports Q3 EPS 49c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VBTX

Veritex

$24.43

-1.07 (-4.20%)

17:06
10/22/18
10/22
17:06
10/22/18
17:06
Earnings
Veritex reports Q3 core EPS 34c, consensus 46c »

Reports Q3 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IBTX

Independent Bank

$56.47

-3.06 (-5.14%)

17:04
10/22/18
10/22
17:04
10/22/18
17:04
Earnings
Independent Bank reports Q3 EPS $1.20, consensus $1.20 »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Brown & Brown »

Brown & Brown reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Simmons First National »

Simmons First National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Earnings
Crane raises FY18 EPS ex-items view to $5.80-$5.90 from $5.60-$5.80 »

Consensus $5.75. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Green Bancorp reports Q3 non-GAAP EPS 49c, consensus 47c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Simmons First National reports Q3 core EPS 61c, consensus 58c »

Reports Q3 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Crane reports Q3 EPS ex-items $1.62, consensus $1.46 »

Reports Q3 revenue $856M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:01
10/22/18
10/22
17:01
10/22/18
17:01
Earnings
Brown & Brown reports Q3 adjusted EPS 38c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Hot Stocks
NBT Bancorp raises quarterly dividend to 26c from 25c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Earnings
NBT Bancorp reports Q3 adjusted EPS 68c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.50

(0.00%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Hot Stocks
Perry Ellis announces completion of its acquisition in $437M transaction »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Earnings
FB Financial reports Q3 adjusted EPS 68c, consensus 72c »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.